An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma (SENSE)

Novartis

Status: Withdrawn

Conditions: Asthma

Treatments: Other: IND/GLY/MF

Study type: Observational

Funder types: Industry

Identifiers

NCT05120986

CQVM149BPT01

Details and patient eligibility

About

This is an observational, descriptive, open-label, prospective, 6-month study including a group of patients with a first prescription of IND/GLY/MF with sensor and a group with a first prescription of IND/GLY/MF without sensor.

Full description

Patients will be invited prospectively and sequentially to participate in the study when attending a participating community pharmacy with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor. Therefore, the invitation for the patient to participate in the study will occur only after the therapeutic decision has taken place

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients aged ≥18 years
• Self-reported diagnosis of asthma
• Individual filling a first prescription of IND/GLY/MF with or without sensor in a participating community pharmacy for himself/herself (excluding caregivers).
• Individual capable and willing to perform the study assessments.

Exclusion criteria

• No exclusion criteria.

Trial design

0 participants in 2 patient groups

IND/GLY/MF with sensor

Description:

Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate with sensor

Treatment:

Other: IND/GLY/MF

IND/GLY/MF without sensor

Description:

Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate without sensor

Treatment:

Other: IND/GLY/MF